Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
Date:2/24/2009

lts of operations could be adversely affected. These factors, and other factors, including, but not limited to those described in ViroPharma's annual report on Form 10-K and quarterly reports on Form 10-Q filed with the Securities and Exchange Commission during 2008, could cause future results to differ materially from the expectations expressed in this press release. The forward-looking statements contained in this press release may become outdated over time. ViroPharma does not assume any responsibility for updating any forward-looking statements.



                            VIROPHARMA INCORPORATED
                        Selected Financial Information


    Consolidated Statements of          Three months         Twelve months
     Operations:                           ended                ended
                                        December 31,          December 31,
    (in thousands, except per           -----------           -----------
     share data)                       2008      2007       2008       2007
                                       ----      ----       ----       ----

    Revenue:
    Net product sales                $50,020   $47,696   $232,307   $203,770
                                      ------    ------    -------    -------
    Revenue                           50,020    47,696    232,307    203,770
                                      ------    ------    -------    -------
    Costs and Expenses:
    Cost of sales (excluding
     amortization of product rights)   2,110     2,034      8,874      8,934
    Research and development          21,197    12,504     66,280     35,869
    Selling, general and
     administrative                   22,357    12,710     65,424     37,051
    Intangible amortization            5,505     1,401     10,809      6,120
    Impairment of fixed assets
     held for sale                     2,265         -      2,265          -
              
'/>"/>
SOURCE ViroPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ViroPharma to Present at Three November Healthcare Conferences
2. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma to Present at Three October Healthcare Conferences
5. ViroPharma to Present at Three September Healthcare Conferences
6. ViroPharma To Acquire Lev Pharmaceuticals
7. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
8. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
9. ViroPharma to Present at Two Upcoming Healthcare Conferences
10. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
11. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 This webinar ... on nonclinical and clinical safety assessment in biosimilars. ... guide a path for biosimilar drug development, however ... of biosimilarity with regards to quality, safety and ... of biosimilar drug development and registration, development strategies ...
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 ... an enhancement to its Online Web Portal for Life ... now have the ability to specify the subject matter ... nearly 50 life science sub-domains. This will help reduce ... and scientific fields, and decrease the likelihood of error. ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 ... – 11 p.m. , Location: Warrington Country Club, 1360 ... Hepatitis B Foundation, the only national nonprofit organization solely ... improving the quality of life for those affected worldwide, ... 11 at Warrington Country Club in Warrington, Pa. ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... initiated coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua ... and marketing proprietary products to serve the wound ... , In late 2012, Alliqua was restructured ... launched the company’s new strategy to become a ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... Dyadic International, Inc. ("Dyadic") (OTC Pink: DYAI), a ... manufacture and sale of enzyme and protein products ... today announced financial results for the quarter ended ... this press release should be read in conjunction ...
... SynCo Bio Partners B.V., one of the leading GMP contract ... is again fully operational and SynCo has produced and released ... expansion of its Class A zone.   The ... in SynCo,s strategy in supporting its clients with new product ...
... for gram, novel carbon nanofiber-filled coatings devised by researchers ... and Texas A&M University outperformed conventional flame retardants used ... by at least 160 percent and perhaps by as ... reported in the journal Polymer ,* suggest that ...
Cached Biology Technology:Dyadic International Reports 2011 Second Quarter Financial Results 2Dyadic International Reports 2011 Second Quarter Financial Results 3Dyadic International Reports 2011 Second Quarter Financial Results 4Dyadic International Reports 2011 Second Quarter Financial Results 5Dyadic International Reports 2011 Second Quarter Financial Results 6Dyadic International Reports 2011 Second Quarter Financial Results 7SynCo Bio Partners Expands the Class A Zone in its Aseptic Filling Facility 2Novel coatings show great promise as flame retardants in polyurethane foam 2
(Date:4/15/2014)... 2014, Irvine, Calif. UC Irvine neurobiologists have found ... when transplanted into the brains of mice with the ... is published in the journal Stem Cells Research ... to work in two different mouse models. , ... dementia, is associated with accumulation of the protein amyloid-beta ...
(Date:4/15/2014)... know as early as 2020 how high sea levels ... team of researchers including Florida International University scientist Rene ... Science Foundation,s (NSF) Florida Coastal Everglades Long-Term Ecological Research ... in ecosystems from coral reefs to deserts, mountains to ... sea level rise is one of the most certain ...
(Date:4/15/2014)... at UC San Diego have succeeded in visualizing ... responsible for growth and resistance to drought. The ... to determine how the hormone helps plants respond ... the continuing increase in the atmosphere,s carbon dioxide, ... appears in the April 15 issue of the ...
Breaking Biology News(10 mins):UCI study finds modified stem cells offer potential pathway to treat Alzheimer's disease 2Long-term predictions for Miami sea level rise could be available relatively soon 2Biologists develop nanosensors to visualize movements and distribution of plant hormone 2
... insect brains, mouth bacteria behaving badly and the hundreds ... just some of the highlights at the Society for ... The annual event takes place on 6-9 September at ... international experts will present cutting-edge scientific research covering a ...
... Carolina State University shows that a species of shellfish widely ... actually increased in size, despite and possibly because of ... found indicates that human activity does not necessarily mean that ... species even a species that people relied on as ...
... filter-feeder, that anchors itself to the sea bed, offers new ... Ice Sheet a region that is thought to be ... for the Census of Antarctic Marine Life (CAML), scientists from ... coastal and deep sea regions around the continent and from ...
Cached Biology News:Archaeological study shows human activity may have boosted shellfish size 2Marine animals suggest evidence for a trans-Antarctic seaway 2
Rabbit polyclonal to Phosphothreonine-X-Phosphotyrosine (HRP) ( Abpromise for all tested applications)....
Anti-ADAMTS-4, disintegrin-like domain Immunogen: Synthetic peptide - KLH conjugated Available Date: 38569...
Leucine-rich repeat-containing G-protein coupled receptor 4...
Mouse monoclonal [4i144] to HLA Class II DQ1 7 ( Abpromise for all tested applications). Antigen: Full length protein (Human): HLA Class 2 Antigen DQ1,7....
Biology Products: